Cargando…

Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies

BACKGROUND: Furmonertinib (AST2818) is a brain penetrant pan-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both EGFR sensitizing mutations and T790M mutation. We report the pooled central nervous system (CNS) efficacy data of furmonertinib in patients with EGFR T7...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Xingsheng, Zhang, Shucai, Ma, Zhiyong, Feng, Jifeng, Wu, Lin, Lv, Dongqing, Zhou, Jianying, Zhang, Xiaodong, Liu, Li, Yu, Qitao, Liao, Wangjun, Zhang, Yiping, Wang, Xiang, Cheng, Ying, Niu, Hongrui, Wang, Ziping, Wang, Dong, Huang, Cheng, Liu, Chunling, Zhao, Hui, Feng, Jian, Li, Jingzhang, Ying, Kejing, Yang, Nong, Qin, Shukui, Hu, Jie, Liu, Fei, Jiang, Yong, Ge, Nan, Shi, Yuankai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148399/ https://www.ncbi.nlm.nih.gov/pubmed/37118803 http://dx.doi.org/10.1186/s12916-023-02865-z

Ejemplares similares

Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report
por: Cheng, Daoan, et al.
Publicado: (2022)

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?
por: Zhang, Shannon S, et al.
Publicado: (2022)

Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer
por: Liu, Xiao-yun, et al.
Publicado: (2020)

A Randomized, Open, Single-Centre, Crossed Study of the Effect of Food on the Pharmacokinetics of One Oral Dose of Alflutinib Mesylate Tablets (AST2818) in Healthy Male Subjects
por: Zhu, Songlin, et al.
Publicado: (2020)

Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS
por: Li, Ying, et al.
Publicado: (2022)

Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
por: Ma, Xiaoting, et al.
Publicado: (2023)

2818. Investigating Urinalysis Criteria that Predict UTI: Impact of age, sex, and urine culture thresholds
por: Advani, Sonali, et al.
Publicado: (2023)

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study
por: Hu, Xingsheng, et al.
Publicado: (2015)

Application of ddPCR in detection of the status and abundance of EGFR T790M mutation in the plasma samples of non-small cell lung cancer patients
por: Zhang, Hui, et al.
Publicado: (2023)

Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs
por: Ma, Li, et al.
Publicado: (2021)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
por: Wang, Yu, et al.
Publicado: (2021)

The association between AST/ALT ratio and all-cause and cardiovascular mortality in patients with hypertension
por: Liu, Hui, et al.
Publicado: (2021)

Angular analysis of $ {B}^0\to {D}^{\ast -}{D}_s^{\ast +} $ with $ {D}_s^{\ast +}\to {D}_s^{+}\gamma $ decays
por: Aaij, Roel, et al.
Publicado: (2021)

The In-Vitro Antitumor Effects of AST-3424 Monotherapy and Combination Therapy With Oxaliplatin or 5-Fluorouracil in Primary Liver Cancer
por: Zhang, Yu, et al.
Publicado: (2022)

Early intervention with Bifidobacterium lactis NCC2818 modulates the host-microbe interface independent of the sustained changes induced by the neonatal environment
por: Lewis, Marie C., et al.
Publicado: (2017)

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy
por: Xu, Ziyi, et al.
Publicado: (2023)

Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review
por: Chen, Ting, et al.
Publicado: (2023)

Test of HQET with B^\ast, B^\ast \ast and lifetime measurements of B_s mesons and beauty baryons at DELPHI
por: Siccama, I
Publicado: (1995)

An AST-ELM Method for Eliminating the Influence of Charging Phenomenon on ECT
por: Wang, Xiaoxin, et al.
Publicado: (2017)

Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma
por: Liu, Yutao, et al.
Publicado: (2020)

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer
por: Xing, Puyuan, et al.
Publicado: (2019)

CircAST: Full-length Assembly and Quantification of Alternatively Spliced Isoforms in Circular RNAs
por: Wu, Jing, et al.
Publicado: (2019)

An updated meta-analysis of AST and ALT levels and the mortality of COVID-19 patients
por: Wang, Ying, et al.
Publicado: (2021)

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2019)

Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance
por: Wang, Mingzhao, et al.
Publicado: (2023)

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
por: Chen, Xuesong, et al.
Publicado: (2023)

Suitability of Surgical Tumor Tissues, Biopsy, or Cytology Samples for Epidermal Growth Factor Receptor Mutation Testing in Non–Small Cell Lung Carcinoma Based on Chinese Population()()
por: Han, Xiaohong, et al.
Publicado: (2014)

AST: Activity-Security-Trust driven modeling of time varying networks
por: Wang, Jian, et al.
Publicado: (2016)

Association between ALT/AST and Muscle Mass in Patients with Type 2 Diabetes Mellitus
por: Ma, Wenjie, et al.
Publicado: (2022)

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study
por: Hu, Xingsheng, et al.
Publicado: (2023)

Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report
por: Jia, Keyi, et al.
Publicado: (2022)

The compound AST-003 could effectively promote apoptosis of renal cell carcinoma cells in vitro
por: Tang, Xingxing, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis
por: Feng, Yu, et al.
Publicado: (2023)

The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study
por: Feng, Yu, et al.
Publicado: (2022)

First Observation of the B ^\ast Dalitz Decay B ^\ast -> B\ e ^+ e ^-
por: DELPHI Collaboration
Publicado: (2018)

Antibiotic Susceptibility Testing (AST) Practices in India: Need for a National AST Forum
por: Borde, Kalyani, et al.
Publicado: (2022)

Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients
por: Yang, Yaning, et al.
Publicado: (2021)

Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report
por: Liu, Yutao, et al.
Publicado: (2018)

Differences in Lung Cancer Treatment Preferences Among Oncologists, Patients and Family Members: A Semi-Structured Qualitative Study in China
por: He, Xiaoning, et al.
Publicado: (2021)

AST Six Pack Premium
por: Basson, Craig Todd
Publicado: (1987)

Cannot write session to /tmp/vufind_sessions/sess_hoejffuissfe8h3epgtbtt2j3n